EyePoint (EYPT) Shares Outstanding (2010 - 2026)
EyePoint (EYPT) posted Shares Outstanding (Entity) of $85999.0 for Q1 2026, up 17.4% sequentially from $73251.0 in Q4 2025, and down 99.88% YoY from $68.8 million in Q1 2025.
Analysis
EyePoint (EYPT) Shares Outstanding (2010 - 2026) Analysis & Trends
EyePoint has reported Shares Outstanding (Entity) for 17 years, with the latest figure at $85999.0 in Q1 2026.
- Quarterly Shares Outstanding (Entity) fell 99.88% year-over-year to $85999.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $85999.0 (down 99.88% YoY) and the FY2025 annual result came in at $73251.0, up 30.11% from the prior year.
- Shares Outstanding (Entity) rose to $85999.0 in Q1 2026 per EYPT's latest filing, from $73251.0 in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $68.8 million in Q1 2025 and troughed at $52913.0 in Q1 2024.
- A 5-year average of $26.7 million and a median of $34.1 million in 2022 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Entity) surged 129946.22% in 2025, then plunged 99.88% in 2026.
- Over 5 years, Shares Outstanding (Entity) stood at $34.1 million in 2022, then gained by 14.15% to $38.9 million in 2023, then tumbled by 99.86% to $56298.0 in 2024, then surged by 30.11% to $73251.0 in 2025, then climbed by 17.4% to $85999.0 in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $85999.0, $73251.0, and $70168.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 61.30 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 398.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 210.89 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 111.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 445.06 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 217.35 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | 86.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 86.54 Mn |
| Mar 31, 2026 | 86.00 Mn |
| Dec 31, 2025 | 73.25 Mn |
| Sep 30, 2025 | 70.17 Mn |
| Jun 30, 2025 | 69.93 Mn |
| Mar 31, 2025 | 69.77 Mn |
| Dec 31, 2024 | 56.30 Mn |
| Sep 30, 2024 | 54.45 Mn |
| Jun 30, 2024 | 53.21 Mn |
| Mar 31, 2024 | 52.91 Mn |
| Dec 31, 2023 | 38.90 Mn |
| Sep 30, 2023 | 38.34 Mn |
| Jun 30, 2023 | 37.58 Mn |
| Mar 31, 2023 | 37.49 Mn |
| Dec 31, 2022 | 37.32 Mn |
| Sep 30, 2022 | 37.34 Mn |
| Jun 30, 2022 | 37.32 Mn |
| Mar 31, 2022 | 37.25 Mn |
| Dec 31, 2021 | 28.76 Mn |
| Sep 30, 2021 | 28.77 Mn |